vs
Side-by-side financial comparison of LXP Industrial Trust (LXP) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
LXP Industrial Trust is the larger business by last-quarter revenue ($86.7M vs $57.3M, roughly 1.5× RHYTHM PHARMACEUTICALS, INC.). LXP Industrial Trust runs the higher net margin — 33.2% vs -83.0%, a 116.1% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -14.0%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 0.3%).
LXP Industrial Trust is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality industrial real estate assets, primarily distribution centers, logistics facilities, and light industrial properties across key markets in the United States. Its tenant base covers e-commerce, third-party logistics, and advanced manufacturing sectors, delivering stable long-term returns for its investors.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
LXP vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.7M | $57.3M |
| Net Profit | $28.8M | $-47.5M |
| Gross Margin | 81.5% | 91.6% |
| Operating Margin | 34.6% | -82.2% |
| Net Margin | 33.2% | -83.0% |
| Revenue YoY | -14.0% | 36.9% |
| Net Profit YoY | — | -9.6% |
| EPS (diluted) | — | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.7M | $57.3M | ||
| Q3 25 | $86.9M | $51.3M | ||
| Q2 25 | $87.7M | $48.5M | ||
| Q1 25 | $88.9M | $32.7M | ||
| Q4 24 | $100.9M | $41.8M | ||
| Q3 24 | $85.6M | $33.3M | ||
| Q2 24 | $85.8M | $29.1M | ||
| Q1 24 | $86.3M | $26.0M |
| Q4 25 | $28.8M | $-47.5M | ||
| Q3 25 | $36.3M | $-52.9M | ||
| Q2 25 | $29.1M | $-46.6M | ||
| Q1 25 | $19.0M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $6.3M | $-43.6M | ||
| Q2 24 | $5.4M | $-32.3M | ||
| Q1 24 | $-269.0K | $-141.4M |
| Q4 25 | 81.5% | 91.6% | ||
| Q3 25 | 82.3% | 89.3% | ||
| Q2 25 | 81.9% | 88.6% | ||
| Q1 25 | 80.7% | 88.8% | ||
| Q4 24 | 85.3% | 90.9% | ||
| Q3 24 | 82.5% | 88.5% | ||
| Q2 24 | 82.0% | 89.9% | ||
| Q1 24 | 82.4% | 89.2% |
| Q4 25 | 34.6% | -82.2% | ||
| Q3 25 | 50.4% | -102.6% | ||
| Q2 25 | 33.7% | -93.4% | ||
| Q1 25 | 21.8% | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | 7.9% | -132.0% | ||
| Q2 24 | 6.9% | -139.2% | ||
| Q1 24 | 1.0% | -538.7% |
| Q4 25 | 33.2% | -83.0% | ||
| Q3 25 | 41.7% | -103.1% | ||
| Q2 25 | 33.2% | -96.1% | ||
| Q1 25 | 21.4% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | 7.4% | -131.2% | ||
| Q2 24 | 6.3% | -110.9% | ||
| Q1 24 | -0.3% | -544.4% |
| Q4 25 | — | $-0.73 | ||
| Q3 25 | $0.12 | $-0.82 | ||
| Q2 25 | $0.09 | $-0.75 | ||
| Q1 25 | $0.06 | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | $0.02 | $-0.73 | ||
| Q2 24 | $0.01 | $-0.55 | ||
| Q1 24 | $-0.01 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $170.4M | $388.9M |
| Total DebtLower is stronger | $1.4B | — |
| Stockholders' EquityBook value | $2.0B | $139.1M |
| Total Assets | $3.5B | $480.2M |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $170.4M | $388.9M | ||
| Q3 25 | $229.7M | $416.1M | ||
| Q2 25 | $71.0M | $291.0M | ||
| Q1 25 | $70.9M | $314.5M | ||
| Q4 24 | $101.8M | $320.6M | ||
| Q3 24 | $55.0M | $298.4M | ||
| Q2 24 | $48.7M | $319.1M | ||
| Q1 24 | $293.8M | $201.2M |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.0B | $139.1M | ||
| Q3 25 | $2.1B | $148.8M | ||
| Q2 25 | $2.1B | $-11.9M | ||
| Q1 25 | $2.1B | $18.9M | ||
| Q4 24 | $2.1B | $21.7M | ||
| Q3 24 | $2.1B | $11.2M | ||
| Q2 24 | $2.1B | $39.3M | ||
| Q1 24 | $2.2B | $61.6M |
| Q4 25 | $3.5B | $480.2M | ||
| Q3 25 | $3.7B | $506.9M | ||
| Q2 25 | $3.7B | $372.7M | ||
| Q1 25 | $3.8B | $386.7M | ||
| Q4 24 | $3.8B | $392.3M | ||
| Q3 24 | $3.9B | $363.6M | ||
| Q2 24 | $3.9B | $381.8M | ||
| Q1 24 | $4.2B | $258.7M |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $188.7M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 6.56× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $188.7M | $-25.4M | ||
| Q3 25 | $63.5M | $-26.6M | ||
| Q2 25 | $44.3M | $-23.3M | ||
| Q1 25 | $39.0M | $-40.4M | ||
| Q4 24 | $211.2M | $-18.8M | ||
| Q3 24 | $64.6M | $-25.2M | ||
| Q2 24 | $38.5M | $-29.1M | ||
| Q1 24 | $38.9M | $-40.7M |
| Q4 25 | 6.56× | — | ||
| Q3 25 | 1.75× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | 2.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.18× | — | ||
| Q2 24 | 7.09× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
